Maternal and neonatal outcomes in a treated versus non- treated cohort of women with Gestational Diabetes Mellitus according to the HAPO 5 and 4 criteria

Background Our aim was to evaluate the treatment effect of gestational diabetes mellitus (GDM) according to the Hyperglycemia and Adverse Pregnancy Outcome group (HAPO) screening. Results The prevalence of GDM, using HAPO 5 was 23.8%. Of these, 72.8% were treated. Comparison of outcomes between treated and untreated patients showed no differences. The prevalence of GDM according to HAPO 4 criteria was 16.9%. In the untreated group, there were more cases of (pre)eclampsia (P=0.038), more admissions to neonatal care department (P=0.036), pregnancy duration was shorter (P=0.05), and Apgar score at five minutes was significantly lower (P=0.019). The outcomes didn't differ in the MAGG (midly aberrant glycemic group). Conclusions Using HAPO 5 criteria in population-based screening doubled the prevalence of GDM. There were no differences between untreated and treated HAPO 5 and MAGG patients, while in the HAPO 4 group there might be a trend of therapy effectiveness.